Seaport Therapeutics
PublicSeaport Therapeutics is now publicly traded
The data on this page reflects Seaport Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 10, 2026
Last Round
Grant
Mar 3, 2026
Total Funding Raised
$440M
Company Overview
Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops innovative neuropsychiatric medicines using its proprietary Glyph technology platform to enhance oral bioavailability and reduce side effects.
Sector
Biotech
Verticals
HealthTech
AI Layer
Non-AI
Keywords
Seaport Therapeutics Comparables
Compare Seaport Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neumora | 76% | |
| Supernus Pharmaceuticals Inc | 76% | |
| Alto Neuroscience | 73% |
Seaport Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Apr 10, 2026 | ||||
| Grant | Mar 3, 2026 | ||||
| Series B | Oct 21, 2024 | ||||
| Series A | Apr 9, 2024 |
Key People
Founding team and executive leadership
Seaport Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CPP Investments | Series B |
| Invus Opportunities | Series B |
| ARCH Venture Partners | Series B, Series A |
| Foresite Capital | Series B |
| T. Rowe Price | Series B |
| ARPA-H | Grant |
| PureTech Health | Series B, Series A |
Recent news
Latest coverage and updates
- attends_eventOct 11, 2026
Seaport Therapeutics, Inc. presents additional pharmacokinetic data at the 39th European College of Neuropsychopharmacology (ECNP) Congress
- attends_eventOct 11, 2026
Seaport Therapeutics, Inc. presents additional pharmacokinetic data from a Phase 1 trial of GlyphAgo at the 39th European College of Neuropsychopharmacology Congress, without establishing clinical benefit.
- is_developingOct 7, 2026
Seaport Therapeutics, Inc. is developing oral versions of treatments for major depressive disorder and generalised anxiety disorder using its Glyph drug-delivery platform.
- receives_financingSep 22, 2026
Seaport Therapeutics, Inc. receives $260M in gross proceeds from a Nasdaq initial public offering in May '26, following private financings completed in 2024.
- is_developingSep 9, 2026
Seaport Therapeutics, Inc. is developing GlyphAllo as a potential treatment for major depressive disorder and plans to submit positive Phase 1 driving-simulation results to the US Food & Drug Administration as part of its ongoing development program.
Seaport Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access